Elinzanetant: New Non-Hormonal Drug for Hot Flashes And Menopause Relief

Elinzanetant: A New Non-Hormonal Option to Reduce Hot Flashes and Improve Menopause Symptoms

Elinzanetant offers non-hormonal relief for hot flashes and night sweats in menopause.

Relief from hot flashes, night sweats, and better sleep with elinzanetant / Freepik

Menopause brings many challenges—hot flashes, night sweats, and sleep disruptions among them. For a long time, hormone therapy has been the go-to treatment, but it's not right for everyone. Now, there's promising evidence that a non-hormonal drug called elinzanetant may significantly ease those symptoms with fewer risks. This article dives into what the research says, how elinzanetant works, who it might help, its safety profile, and what’s next in bringing it to patients. Let’s unpack the science in simple terms.

What Are Vasomotor Symptoms in Menopause?

Vasomotor symptoms (VMS) refer to hot flashes and night sweats that many women experience during menopause. They are caused by hormonal changes—especially declining estrogen—that affect the body’s temperature regulation systems. These symptoms can disrupt sleep, mood, and daily life. According to major health sources such as NIH, up to 80% of menopausal women report VMS, and many suffer moderate to severe symptoms.

What Is Elinzanetant?

Elinzanetant (also under the brand name Lynkuet) is an investigational drug developed by Bayer (in collaboration with others) that targets two receptor types in the brain: NK-1 and NK-3 (neurokinin receptors). By blocking these receptors, elinzanetant is believed to reduce the overactivity in certain neurons (called KNDy neurons) that contribute to hot flashes and night sweats, without using hormones.

Key Clinical Study: OASIS-3 Trial

Design and Population

The OASIS-3 trial was a Phase III, randomized, double-blind, placebo-controlled study carried out at 83 sites across North America and Europe. It enrolled about 628 postmenopausal women aged 40-65 years who were experiencing moderate to severe VMS. The participants took either 120 mg of elinzanetant once daily or placebo, over 52 weeks.

Primary Outcomes

By week 12, those taking elinzanetant experienced a **~73.8%** reduction in frequency and severity of moderate to severe hot flashes and night sweats, compared with about **47.0%** in the placebo group. By around week 50, women on the drug were averaging around **1.4 episodes per day**, while the placebo group still had about **3.5 episodes per day**.

Secondary and Exploratory Outcomes

Improvement in sleep disturbance over 52 weeks.
Better menopause-related quality of life (MENQOL questionnaire) over the year.
No evidence of damage to bone density or meaningful changes in markers of bone turnover.

Safety Profile

Overall, elinzanetant was well tolerated. Some side effects were more common in the treatment group than placebo (around 30.4% vs. 14.6%), including somnolence, fatigue, and headache. But importantly, there were **no signs of liver toxicity**, no endometrial hyperplasia or malignancy, and no significant adverse effects on bone density.

How Elinzanetant Compares to Other Treatments

Hormone therapy (HT) remains the most effective known treatment for hot flashes, but it carries certain risks and is unsuitable for many women (e.g., those with certain cancers, cardiovascular risks, or personal preference). Non-hormonal options (antidepressants, lifestyle changes, other medications) often provide modest relief.

A similar non-hormonal drug, fezolinetant (brand name Veozah), which targets only the NK-3 receptor, has already been approved by the FDA and EU for moderate to severe VMS. Fezolinetant also shows reduction in hot flashes and quality-of-life benefits, but its side effect profile includes possible liver enzyme elevation.

The advantage of elinzanetant may be its dual receptor action (NK-1 plus NK-3), which seems to provide strong relief and sustained effects over a longer period (52 weeks) without the hormonal risks. But direct head-to-head trials are limited so far.

Who Might Benefit from Using Elinzanetant?

Based on current evidence, women who might especially benefit include:

Postmenopausal women (aged around 40-65) with moderate to severe hot flashes or night sweats.
Women who prefer non-hormonal treatments, or who cannot use hormone therapy due to risk factors like history of breast cancer, cardiovascular disease, or personal or family concerns.
Those whose symptoms (hot flashes, night sweats) significantly disrupt sleep and quality of life.

Limitations and Considerations

Though the results are promising, several limitations are important to understand:

The study was limited in diversity: while a good mix of participants, some ethnic groups (e.g. Asian, Native Hawaiian or Pacific Islander) were underrepresented.
The trial was not primarily powered to definitively test secondary outcomes (sleep, quality of life) though those endpoints showed improvement.
Medical costs, availability, and regulatory approval may vary by country. As of now, elinzanetant has been approved in some places (UK, Canada) but is under review in others.
Long-term effects beyond one year are still to be fully understood. Also, interactions with other medications, contraindications, and patient-specific risks (e.g., liver or kidney issues) need further study.

Regulatory Status and What’s Next

Elinzanetant is branded as Lynkuet in some markets. It has been approved for use in the UK and Canada. In the United States, the FDA is reviewing the drug and has extended its review by up to 90 days recently; no major concerns were raised about general approvability.

Further research is ongoing to clarify its use in special populations (for example, women with cancer or on endocrine therapy), to monitor its long-term safety, and possibly compare it head-to-head with hormone therapy or other non-hormonal options.

Practical Advice for Patients and Healthcare Providers

If you are a healthcare provider or patient considering elinzanetant, here are some practical points:

Discuss whether hormone therapy is appropriate or not, based on medical history, preferences, and risk factors.
Consider starting with non-hormonal drugs like elinzanetant in women who cannot use hormones or want alternatives.
Monitor symptoms carefully: track frequency and severity of hot flashes and night sweats, sleep quality, mood, and side effects.
Check liver function and bone health as part of baseline and follow-up, even though major issues weren’t found in the 52-week trial.
Manage expectations: relief may begin within weeks; full effect and sustained relief are likely over months.

FAQ

Is elinzanetant hormonal therapy?

No. Elinzanetant is a **non-hormonal** drug. It works by blocking NK-1 and NK-3 receptors in the brain rather than supplying or mimicking hormones. This helps avoid many of the risks associated with hormone therapy.

How fast does elinzanetant begin to work?

Some improvements are seen relatively quickly (within weeks). In OASIS-3, there was a significant reduction in frequency and severity of hot flashes by week 12, and even earlier benefits were noted in prior trials (e.g. weeks 1-4 in OASIS-1 and 2).

What side effects should I expect?

Common side effects in trials included somnolence (sleepiness), fatigue, headache. Most were mild or moderate. Serious side effects were rare. The drug did not show liver toxicity or bone density loss in the 52-week study.

Can I use elinzanetant if I have had breast cancer or other hormone-sensitive cancers?

Many patients excluded from trials had a history of certain cancers. While non-hormonal approaches are attractive for those with hormone-sensitive cancers, data on elinzanetant in these populations are more limited. A separate study is exploring its use in women on endocrine therapy for breast cancer.

Is elinzanetant available now?

Elinzanetant (Lynkuet) has been approved in some jurisdictions (e.g. UK, Canada). In the US, its application is under review. Approvals elsewhere and pricing vary. Talk to your healthcare provider about local availability.

How does elinzanetant compare to fezolinetant (Veozah)?

Both are non-hormonal treatments targeting neurokinin receptors: fezolinetant works mainly on NK-3, while elinzanetant blocks both NK-1 and NK-3. Early evidence suggests elinzanetant may have stronger or more sustained symptom relief, but comparative trials are limited. Each has its own safety profile which should be discussed with a healthcare provider.

The emergence of elinzanetant offers hope for women experiencing moderate to severe hot flashes and night sweats who are seeking non-hormonal alternatives. The OASIS-3 trial provides strong evidence for its efficacy over a year, showing large reductions in symptom frequency and severity, with a favorable safety profile. While longer‐term data and wider populations are still needed, the current research marks an important step in expanding treatment options for menopause. Patients and clinicians should engage in careful, individualized discussions about benefits, risks, availability, and cost.

ZenHealth Tips